MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
... 33.8 percent for placebo (p<0.0001);
free: 46.6 percent of patients who received ... include pain relief, and being phonophobia, photophobia
and nausea free at two hours after dosing. ... include recurrent headaches, nausea, vomiting, photophobia
(sensitivity to light) and phonophobia ...
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
... endpoints will be pain relief at two hours, and freedom from
and phonophobia at two hours.
MAP0004 is a proprietary ... 24 hours. The
study also demonstrated efficacy trends in treating nausea, photophobia
phonophobia. Based on these results, as well as independent research ...
Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference
... to treat cystinosis can cause serious health consequences, including renal failure (and resultant kidney transplant), growth failure, rickets, photophobia
and blindness. Cystinosis is typically treated with an immediate-release form of cysteamine bitartrate, which is currently the only therapeutic ...
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
... at 24 hours in a treatment received population. The trial also showed clinically significant trends in the resolution of phonophobia, photophobia
and nausea at certain time points. MAP0004 was shown in the trial to be well tolerated and no serious adverse events were reported.
ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
... Drug Administration (FDA) for
Xibrom(TM) QD (once-daily). The Company is seeking approval for Xibrom QD
as a treatment for inflammation, pain, and photophobia
Xibrom(TM) (bromfenac ophthalmic solution)
Xibrom is a topical non-steroidal anti-inflammatory compound for ...
Combination Therapy More Effective Than Monotherapy for Treating Migraine
... than placebo for headache relief at two hours after dosing (study 1, 65 percent vs. 28 percent; and study 2, 57 percent vs. 29 percent;), absence of photophobia
(sensitivity to light) at two hours (58 percent vs. 26 percent; and 50 percent vs. 32 percent;), and absence of phonophobia (sensitivity to sound) at ...
Photophobia in Medical Technology
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
... 24 hours. The study also
demonstrated efficacy trends in treating nausea, photophobia
phonophobia, the other key measurements in treating migraine.
This ... primary efficacy endpoints will be pain relief, and freedom
from nausea, photophobia
and phonophobia as measured at two hours after
dosing. MAP will also ...
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
... relief of migraine-associated symptoms such as
nausea, vomiting, photophobia
(sensitivity to light) and phonophobia
(sensitivity to sound), as well as ... pain relief at two hours, pain-free at two hours and relief of
and phonophobia. About AK Receptor Antagonists AMPA/kainate (AK) ...
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
In addition, both Phase III studies showed highly statistically significant results in the proportion of subjects with no photophobia
(light sensitivity) at every study visit post-cataract surgery. This is in concordance with previous clinical trials with Xibrom. The studies also ...
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
... of the condition is anterior uveitis, associated primarily
with inflammation of the iris. If left untreated, uveitis can cause
debilitating pain and photophobia
as well as permanent damage and vision
loss due to the development of glaucoma, cataract or retinal edema.
Dr. Kaufman's poster, "Data from Trials ...
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
... relief in as fast as ten minutes, with relief sustained through at
least 24 hours. The study also demonstrated efficacy trends in treating
and phonophobia, the other key measurements in treating
The therapeutic agent in MAP0004 is dihydroergotamine (DHE), which has
a long ...
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
... ten minutes of
dosing, and this relief was sustained through at least 24 hours. The study
also demonstrated efficacy trends in treating nausea, photophobia
phonophobia. Based on these results, as well as independent research that
concludes that patients prefer migraine therapies providing fast ...
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
... traditionally required for regulatory
approval. These endpoints included pain relief at two hours, pain-free at
two hours and relief of nausea, photophobia
and phonophobia. About AK Receptor Antagonists AK receptors are part of the glutamate biological pathway that
transmits pain signals to the brain. ...
Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data
Published in JAMA
placebo on the following variables:
-- Headache relief
-- Absence of phonophobia (sensitivity to sound)
-- Absence of photophobia
(sensitivity to light)
-- Absence of nausea
The second objective was to assess the sustained effect of
Trexima from two through 24 hours ...
Photophobia in Medical Definition
Visual disturbances and blindness
Amblyopia - Leber's congenital amaurosis - Subjective ( Asthenopia , Hemeralopia , photophobia
, Scintillating scotoma ) - Diplopia - Scotoma - Anopsia ( Binasal hemianopsia , Bitemporal hemianopsia , Homonymous hemianopsia , ...
Photophobia in Medical Dictionary
: Painful oversensitivity to light. For example, there is photophobia
in measles ( rubeola ). Keeping the lights dim ... may be useful. Sunglasses may also help. photophobia
; Light sensitivity; Light hurts the eyes ; ...
... Guide > Eye Pain Eye Pain - ... Eye pain . Sensitivity to light ( photophobia
). Decreased vision in all or part of the vision field. Blurred ... there a fever ? Is there a stiff neck? Are the eyes light-sensitive ( photophobia
)? Is there eye pain ? Is there loss of vision ? ...
... sign of the syndrome in infancy is often extreme light sensitivity ( photophobia
) and a wobbling of the eyes ( nystagmus ). From 4 to 10% of ... nystagmus (recurrent flickering back-and-forth eye movements ), photophobia
, amaurosis, color blindness , ... Nystagmus (rhythmic jerking ...
... Los Angeles, CA. Review provided by VeriMed Healthcare Network. Rapid eye movements ( nystagmus ) Strabismus ( eyes not tracking properly) photophobia
(avoidance of light because of discomfort) Decreased visual acuity or even functional blindness ... The involuntary eye movements of ...
... syndrome . But these are called irritant tears, and are produced as a reflex reaction to the syndrome . excessive tearing light sensitivity ( photophobia
) closure of one or both eyes in the light cloudy, enlarged cornea one eye may be larger than the other vision loss ... - Tearing - ...
Photophobia in Biological Technology
Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
... damage and vision loss due to the development of glaucoma, cataract, or retinal edema. In addition to potential vision loss, the severe pain and photophobia
that accompany anterior uveitis can be debilitating.
Durezol (difluprednate ophthalmic emulsion) 0.05% is a topical ...
MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
... safety and
efficacy of MAP0004 as a potential acute treatment for migraine. The primary
efficacy endpoints are pain relief and freedom from nausea, photophobia
phonophobia as measured at two hours after dosing. The study is also
evaluating earliest onset of pain relief, pain relief at 10 minutes, ...
Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
... Failure to treat the disease
can cause serious health consequences, including renal failure and
resultant kidney transplant, growth failure, rickets, photophobia
In collaboration with the University of California, San Diego ("UCSD"),
supported by the Cystinosis Research Foundation ("CRF"), ...
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
... December of 2007 after announcing, earlier in the year, positive Phase III results for Xibrom QD as a treatment for inflammation, pain, and photophobia
following cataract surgery
-- Announced statistically significant Phase II/III study results for Bepreve in treating ocular itching and ...
Photophobia in Biological Definition
... that often come with age, the gain is generally thought be out-weighed by the trauma.
The lack of pigment in the eye generally leads to ocular photophobia
or hyper-photo-sensitivity . This is due not so much by the iris allowing stray light into enter the eye, as to a lack of pigment within the eye, ...